Publications by authors named "Dhiraj Gambhire"
Article Synopsis
- The DESTINY-Breast02 trial aimed to evaluate the effectiveness and safety of trastuzumab deruxtecan compared to physician's choice treatments in patients with HER2-positive metastatic breast cancer who had previously been treated with trastuzumab emtansine.
- Conducted at 227 sites across multiple countries, this phase 3 trial involved randomly assigning 608 eligible patients to either trastuzumab deruxtecan or a choice of other drugs, with the primary goal of assessing progression-free survival.
- Findings showed that 608 patients were analyzed, with a median age of 54.2 years, highlighting the trial's significance for a population lacking treatment options.
Article Synopsis
- A study was conducted on patients with "HER2-low" metastatic breast cancer, which means they have low levels of HER2 that could potentially be treated, but existing therapies were not effective.
- In the trial, patients were randomly assigned to receive either trastuzumab deruxtecan or standard chemotherapy after having one or two previous treatments; the main goal was to measure how long patients remained free from disease progression.
- Results showed that those treated with trastuzumab deruxtecan had significantly longer progression-free survival (10.1 months vs. 5.4 months) and overall survival (23.9 months vs. 17.5 months) compared to the standard chemotherapy group, despite a high rate of serious adverse
This phase Ib study (NCT02179918) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137 in combination with the humanized, PD-1-blocking IgG4 mAb pembrolizumab in patients with advanced solid tumors. Utomilumab (0.45-5.
View Article and Find Full Text PDFIn this era of precision oncology, there has been an exponential growth in the armamentarium of genomically targeted therapies and immunotherapies. Evaluating early responses to precision therapy is essential for "go" versus "no go" decisions for these molecularly targeted drugs and agents that arm the immune system. Many different response assessment criteria exist for use in solid tumors and lymphomas.
View Article and Find Full Text PDFObjective: Unprovoked "A-β+" Ketosis-Prone Diabetes (KPD), a unique diabetic syndrome of adult-onset, obesity and proneness to ketoacidosis, is associated with rapid recovery of β cell function and insulin-independence. Whereas most patients experience prolonged remission, a subset relapses early to insulin dependence. We sought to define factors associated with early relapse.
View Article and Find Full Text PDFDual PPARα/γ can improve both metabolic effects and minimized the side effects caused by either PPARα or PPARγ agonist. The PRESS V study was aimed to evaluate the safety, tolerability, and efficacy of saroglitazar 2 mg and 4 mg capsules (Lipaglyn™; Zydus Code: ZYH1) as compared to high dose pioglitazone in patients with diabetic dyslipidemia. In this 26-week double-blind, parallel arm, phase 3 study patients with hypertriglyceridemia with type 2 diabetes mellitus (BMI > 23 kg/m; hypertriglyceridemia: TG > 200 to 400 mg/dL; glycosylated hemoglobin [HbA] >7 to 9%) were enrolled from 14 sites in India.
View Article and Find Full Text PDF